- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- GT005
- Drug
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 72
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Degeneration, Geographic Atrophy
- Interventions
- IONIS-FB-LRx, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 47 more
- Conditions
- Geographic Atrophy
- Interventions
- APL-2, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
- Conditions
- Atrophy, Geographic
- Interventions
- GSK933776, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin
- Drug
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Geographic Atrophy
- Interventions
- OCU410
- Genetic
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
- Conditions
- Geographic Atrophy
- Interventions
- No intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Pensacola, Florida • Chesterfield, Missouri • Charlotte, North Carolina + 8 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- ADX-038, Placebo
- Drug
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 18 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- FWY003, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Huntington Beach, California • Sacramento, California • Santa Barbara, California + 11 more
- Conditions
- Macular Degeneration, Age-related, Geographic Atrophy
- Interventions
- BI 771716, Pegcetacoplan, Sham comparator to BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Geographic Atrophy (GA)
- Interventions
- Pozelimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • East Weymouth, Massachusetts • Austin, Texas + 2 more
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab, Sham Comparator
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 60 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- 400 µg Brimonidine Implant, Sham
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
- Conditions
- Macular Degeneration, Age-Related, Geographic Atrophy
- Interventions
- Galegenimab, Sham Control
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 65 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- JNJ-81201887, Sham Procedure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 45
- States / cities
- Tucson, Arizona • Fullerton, California • La Jolla, California + 40 more
- Conditions
- Geographic Atrophy
- Interventions
- SAR446597, Sham Comparator
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 31
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- CNTO 2476, iTrack Model 275 micro catheter
- Biological · Procedure
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 2
- States / cities
- Arcadia, California • Philadelphia, Pennsylvania
- Conditions
- Geographic Atrophy, Age Related Macular Degeneration
- Interventions
- IONIS-FB-Lrx, Placebo (sterline saline 0.9%)
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 20 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- PEGCETACOPLAN (APL-2)
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 792 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 99
- States / cities
- Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Complement Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Mountain View, California • Oak Forest, Illinois • Springfield, Illinois + 7 more
- Conditions
- Geographic Atrophy
- Interventions
- NGM621
- Biological
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
- Conditions
- Geographic Atrophy
- Interventions
- RO7303359
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Mountain View, California • Sacramento, California • Santa Maria, California + 9 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Interventions
- GEM103
- Biological
- Lead sponsor
- Gemini Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-2, Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Oxnard, California • Austin, Texas + 2 more